VEGFA and hepatocellular carcinoma: Previous studies have also shown that sorafenib is an effective poly-kinase inhibitor that targets the vascular endothelial growth factor (VEGF) receptor, and therefore, it is expected to have a synergistic effect when combined with TACE in the treatment of HCC [2].